ONCS - OncoSec Medical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3700
+0.1300 (+5.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.2400
Open2.3200
Bid0.0000 x 1100
Ask6.2900 x 1800
Day's Range2.3000 - 2.4300
52 Week Range1.6000 - 9.5000
Volume261,785
Avg. Volume265,609
Market Cap25M
Beta (3Y Monthly)2.33
PE Ratio (TTM)N/A
EPS (TTM)-4.2920
Earnings DateDec 6, 2017 - Dec 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.67
  • Business Wire

    OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, released a video featuring its President and Chief Executive Officer, Daniel J. O’Connor, discussing why shareholders should vote in favor of the proposed strategic transaction with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP") and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex") (the "Transaction").

  • Business Wire

    Alpha Holdings Urges OncoSec Stockholders to Vote Against China Grand Takeover Proposal at Special Meeting of Stockholders

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today filed a definitive proxy statement and sent a letter to stockholders of OncoSec opposing the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand"). Alpha urges OncoSec stockholders to vote "AGAINST" the transaction by returning the BLUE proxy card before the Special Meeting of Stockholders, currently scheduled for January 17, 2019.

  • Business Wire

    Alpha Holdings Comments on OncoSec’s Inability to Defend China Grand Takeover

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today issued the following response to OncoSec’s most recent announcements.

  • Business Wire

    OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing

    OncoSec Medical Incorporated (ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme buried in Alpha Holdings, Inc.’s (“Alpha”) revised preliminary proxy statement filed on December 3, 2019. If we obtain a sufficient number of votes AGAINST the proposal being submitted at the Special Meeting for stockholders to clearly defeat the proposal, we will vote your shares.

  • Business Wire

    OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements

    OncoSec Medical Incorporated (ONCS), (the “Company” or “OncoSec”) a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to shareholders. OncoSec Medical Incorporated (“OncoSec”, the “Company”, “we” or “our”) has scheduled a Special Meeting of Shareholders on January 17, 20201  to vote on our proposed strategic transaction (the “Transaction”) with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”) and its U.S. affiliate, Sirtex Medical US Holdings, Inc. (“Sirtex”).

  • Business Wire

    Alpha Holdings Wins in Nevada Court and Comments on OncoSec’s Cynical Attempt to Push Through China Grand Deal

    Alpha Holdings, Inc. (117670.KQ) (“Alpha Holdings”), the largest stockholder of OncoSec Medical Incorporated (ONCS) (“OncoSec” or the “Company”), with an approximate 15.1% ownership stake, today announced that the Eighth Judicial District Court in Clark County, Nevada, has denied, in their entirety, the OncoSec1 and China Grand2 defendants’ motions to dismiss the pending class action lawsuit filed by Alpha Holdings on behalf of all OncoSec stockholders. The Court also directed OncoSec to produce the stockholder lists demanded by Alpha Holdings, including the list of non-objecting beneficial owners.

  • OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference
    PR Newswire

    OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference

    OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5, 2019, at 1:30 p.m. Eastern Time in New York, NY.

  • Business Wire

    Alpha Holdings Opposes OncoSec Defendants’ Motions to Dismiss Shareholder Class Action Complaint

    Alpha Holdings, Inc. (117670.KQ) (“Alpha Holdings”), the largest stockholder of OncoSec Medical Incorporated (ONCS) (“OncoSec” or the “Company”), with an approximate 15.1% ownership stake, today filed with the District Court in Clark County, Nevada, its briefs in opposition to the OncoSec and China Grand defendants’1 motions to dismiss the pending class action lawsuit filed by Alpha Holdings on behalf of all OncoSec stockholders.

  • Business Wire

    Alpha Holdings Provides Update on Opposition to OncoSec Takeover Proposal

    Alpha Holdings, Inc. (117670.KQ) (“Alpha Holdings”), the largest stockholder of OncoSec Medical Incorporated (ONCS) (“OncoSec” or the “Company”), with an approximate 15.1% ownership stake, today provided an update with respect to its opposition of the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings (“CGP”) and Sirtex Medical US Holdings, Inc. (“Sirtex”), an affiliate of GCP (together, “China Grand”). On October 29, 2019, Alpha Holdings filed two lawsuits against OncoSec in the District Court of Clark County, Nevada.

  • OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO™ KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
    PR Newswire

    OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO™ KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

    Robust safety data across hundreds of patients in multiple types of cancer demonstrates the consistent safety profile of TAVO as a well-tolerated cancer immunotherapy SAN DIEGO and PENNINGTON, N.J. , Nov. ...

  • OncoSec to Present TAVO™ Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
    PR Newswire

    OncoSec to Present TAVO™ Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

    Additional global safety updates across all TAVO™ clinical studies SAN DIEGO and PENNINGTON, N.J. , Nov. 5, 2019 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company ...

  • Business Wire

    Alpha Holdings Files Class Action and Books and Records Lawsuits Against OncoSec

    Alpha Holdings, Inc. (117670.KQ) (“Alpha Holdings”), the largest stockholder of OncoSec Medical Incorporated (ONCS) (“OncoSec” or the “Company”), with an approximate 15.15% ownership stake, today announced that it has filed two lawsuits in the District Court of Clark County, Nevada, against OncoSec and its Board of Directors. The first is a class action lawsuit filed by Alpha Holdings on behalf of all OncoSec stockholders, alleging that the OncoSec board members have breached their fiduciary duties by agreeing to a takeover proposal (the “Takeover Proposal”) with a wholly-owned subsidiary of China Grand Pharmaceuticals and Healthcare Holdings (“CGP”) and Sirtex Medical US Holdings, Inc. (“Sirtex”), an affiliate of CGP, and breached their duty of candor by failing to fully and fairly disclose all material information regarding the Takeover Proposal.

  • OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market
    PR Newswire

    OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market

    SAN DIEGO and PENNINGTON, N.J., Oct. 21, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a company developing late-stage intratumoral cancer immunotherapies, today released the following Letter to Shareholders from CEO Daniel J. O'Connor regarding the recently-announced strategic transaction with Grand Decade Developments Limited, a direct wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) (0512.HK) and its affiliate, Sirtex Medical US Holdings, Inc. (Sirtex). On Thursday, October 10, 2019, we announced an important strategic transaction with China Grand Pharmaceutical and Healthcare Holdings (CGP) and its U.S. affiliate, Sirtex Medical Holdings, Inc. (Sirtex) that we believe is in the best interest for all OncoSec shareholders1.  In summary, upon approval of our shareholders, this transaction would bring a $30 million cash infusion at a premium to our recent price per share and fund both of our ongoing KEYNOTE clinical trials of TAVO in combination with Merck's KEYTRUDA® to completion.

  • OncoSec Announces New Peer-Reviewed Data for TAVO™ in Virus-Associated Skin Cancer Published in Clinical Cancer Research
    PR Newswire

    OncoSec Announces New Peer-Reviewed Data for TAVO™ in Virus-Associated Skin Cancer Published in Clinical Cancer Research

    SAN DIEGO and PENNINGTON, N.J., Oct. 15, 2019 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of new data in Clinical Cancer Research which highlighted TAVO™ (intratumoral plasmid IL-12 with electroporation) as a safe, feasibility and clinically meaningful therapy in patients with Merkel cell carcinoma (MCC), an aggressive form of skin cancer. "These data demonstrate that intratumoral delivery of plasmid interleukin-12 with electroporation (TAVO™) as a monotherapy has the potential to have a durable impact on skin cancers such as Merkel cell carcinoma.

  • 4 Stocks With More Than 20% Price Increases on Thursday
    GuruFocus.com

    4 Stocks With More Than 20% Price Increases on Thursday

    Markets soar on US-China trade talk optimism Continue reading...

  • OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries
    PR Newswire

    OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries

    PENNINGTON, N.J., Oct. 10, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a late-stage intratumoral cancer immunotherapy company, today announced it entered into a strategic transaction with Grand Decade Developments Limited (Grand Decade), a direct, wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) (0512.HK), and its affiliate, Sirtex Medical US Holdings, Inc. (Sirtex). OncoSec will receive a $30 million investment from CGP and its affiliate Sirtex at $2.50 per share, an approximate 25% premium to the average share price over the last 20 days since October 9, 2019.

  • OncoSec to Present at the Cantor 2019 Global Healthcare Conference
    PR Newswire

    OncoSec to Present at the Cantor 2019 Global Healthcare Conference

    SAN DIEGO and PENNINGTON, N.J. , Sept. 26, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced ...

  • OncoSec to Present at the Ladenburg Thalmann 2019 Healthcare Conference
    PR Newswire

    OncoSec to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    SAN DIEGO and PENNINGTON, N.J. , Sept. 20, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced ...

  • OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference
    PR Newswire

    OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    SAN DIEGO and PENNINGTON, N.J. , Sept. 6, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced ...

  • PR Newswire

    OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies

    SAN DIEGO and PENNINGTON, N.J., July 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 15/561,915. The allowed patent application covers methods of treating a patient having treatment-refractory, cutaneous or subcutaneous, cancerous tumors, that involve injecting the tumor with a plasmid coding for an immunostimulatory cytokine (e.g. "The claims granted by the USPTO provide OncoSec with broad-based protection on the very valuable combination of intratumoral cytokines, electroporation and checkpoint inhibitor therapy.  We continue to fortify the patent portfolio around our technology, which employs electroporation and local cytokine delivery and continues to demonstrate impressive systemic tumor responses, particularly when combined with checkpoint inhibitors," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec.

  • OncoSec Issues Letter to Shareholders
    PR Newswire

    OncoSec Issues Letter to Shareholders

    SAN DIEGO and PENNINGTON, N.J , July 16, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today published ...

  • OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
    PR Newswire

    OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers

    SAN DIEGO and PENNINGTON, N.J., June 27, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute, a world-leading cancer research and treatment institution, and The Marasco Laboratory, a cutting-edge CAR T-cell research laboratory led by Wayne Marasco, M.D., Ph.D., a renowned cancer immunology researcher, to develop CAR T-cell therapies for triple-negative breast cancer and other solid tumor cancers.

  • OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator
    PR Newswire

    OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator

    IVM is a powerful tool enabling real-time in vivo visualization of important immune activation and movements in tumor microenvironment driven by TAVO-PLUS SAN DIEGO , and PENNINGTON, N.J. , June 17, 2019 ...

  • OncoSec to Present Immunological Data at World Pharma Week 2019
    PR Newswire

    OncoSec to Present Immunological Data at World Pharma Week 2019

    Compelling Data from Multiple Clinical Trials Using Company's Biomarker Technology Support Novel Approach to Immune Resistance Mechanisms in Cancer SAN DIEGO and PENNINGTON, N.J. , June 13, 2019 /PRNewswire/ ...